{"filings":[{"id":1138328,"accession_number":"0001628280-26-044263","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2026-06-18T20:05:31+00:00","items":["5.07"],"status":"ready","headline":"Sionna Therapeutics annual meeting results: all director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four Class II directors elected: H. Edward Fleming, Marcella Kuhlman Ruddy, Peter A. Thompson, Joanne Louise Viney.","Ratification of Deloitte & Touche LLP as independent auditor for FY 2026 approved with 43,291,215 votes for.","Meeting held June 17, 2026; 45,142,330 shares outstanding as of record date April 21, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22282,"accession_number":"0001628280-26-033870","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2026-05-12T11:08:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.","R&D expenses $19.0M (vs. $13.7M), G&A expenses $10.6M (vs. $6.0M) year-over-year.","Cash and equivalents $289.9M; expected to fund operations into 2028.","Phase 2a POC trial of SION-719 fully enrolled; topline data expected summer 2026.","Phase 1 dual-combination trial of SION-451 also on track for topline data summer 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112153,"accession_number":"0001628280-26-012993","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sionna Therapeutics Q4 2025 net loss $20.4M; cash $310.3M funds into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.4M (Q4) and $75.3M (FY 2025) vs $15.8M and $61.7M in 2024.","Cash and equivalents $310.3M as of Dec 31, 2025; expected to fund operations into 2028.","Phase 2a PreciSION CF trial of SION-719 on track; topline data expected mid-2026.","Phase 1 dual combo trial of SION-451 with SION-2222/SION-109 on track; data mid-2026.","R&D expenses $15.2M (Q4) and $60.3M (FY); G&A expenses $8.4M (Q4) and $28.7M (FY)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128761,"accession_number":"0001628280-25-049246","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sionna Q3 net loss $20.3M; starts Phase 2a trial for SION-719; cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.3M in Q3 2025 versus $25.4M in Q3 2024; R&D expenses fell to $16.0M from $24.6M due to prior year license charge.","Cash and equivalents totaled $325.0M as of Sep 30, 2025, expected to fund operations into 2028.","Initiated PreciSION CF Phase 2a proof-of-concept trial for SION-719 as add-on to standard of care in cystic fibrosis; topline data expected in mid-2026.","Initiated Phase 1 trial evaluating SION-451 in proprietary dual combinations with CFTR correctors SION-2222 and SION-109; topline data mid-2026.","Appointed Caroline Stark Beer as Chief Business Officer in September 2025."],"consensus_eps_estimate":-0.494,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145509,"accession_number":"0002036042-25-000044","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sionna Therapeutics Q2 net loss $18.1M; positive Phase 1 data for NBD1 stabilizers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.1M in Q2 2025 vs $8.6M in Q2 2024; R&D expenses $15.4M.","Cash and equivalents $337.3M as of June 30, 2025; funding expected into 2028.","Positive Phase 1 data for SION-719 and SION-451: well tolerated, exceeded PK targets.","Phase 2a trial of SION-719 as add-on to CF standard of care on track for H2 2025; topline data mid-2026.","Phase 1 dual combination trial of SION-451 with galicaftor and SION-109 on track for H2 2025; data mid-2026."],"consensus_eps_estimate":-0.5661,"consensus_eps_actual":-980.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163892,"accession_number":"0002036042-25-000018","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sionna Therapeutics annual meeting elects three Class I directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Joshua Resnick, Bruce Booth, and Lucian Iancovici as Class I directors, each with over 42 million votes for.","Ratification of Deloitte & Touche as independent auditor for FY2025 passed with 43,189,421 votes for, none against.","Record date April 15, 2025; 44,124,394 shares outstanding; broker non-votes of 496,255 on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163891,"accession_number":"0001193125-25-134462","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sionna reports positive Phase 1 data for NBD1 stabilizers SION-719 and SION-451; advances both to next trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Both SION-719 and SION-451 were generally well tolerated with no serious adverse events or discontinuations.","Both compounds met exposure thresholds from preclinical CFHBE model, indicating potential for clinically meaningful benefit.","SION-719 to advance to Phase 2a proof-of-concept add-on trial in CF patients; initiation H2 2025, topline mid-2026.","SION-451 to advance to Phase 1 dual combination trial with SION-2222 and SION-109; initiation H2 2025, topline mid-2026.","FDA cleared IND for SION-719; first subject dosed in midazolam drug-drug interaction study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163890,"accession_number":"0002036042-25-000014","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sionna Therapeutics Q1 net loss $16.5M; cash $354.7M; Phase 1 dosing complete for two NBD1 stabilizers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.5M for Q1 2025, up from $11.8M in Q1 2024; R&D expenses $13.7M vs $10.2M.","Cash and cash equivalents $354.7M as of March 31, 2025, including $199.6M net IPO proceeds; runway into 2028.","Phase 1 dosing completed for SION-719 and SION-451; topline data expected in Q2 2025.","Phase 2a POC trial and at least one dual combination MAD trial on track for H2 2025; topline data mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-620.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181755,"accession_number":"0001193125-25-058306","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sionna Therapeutics FY2024 net loss $61.7M; cash $168M plus $199.6M IPO net proceeds extend runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $15.8M, full year $61.7M vs $47.3M in 2023; R&D spend $57.3M.","Cash, equivalents and marketable securities $168.0M as of Dec 2024; excluding $199.6M net IPO proceeds from February 2025.","Upsized IPO raised $219M gross ($199.6M net) in Feb 2025; shares trading on Nasdaq under SION.","Phase 1 MAD dosing completed for SION-451; final MAD cohort for SION-719 planned; topline data expected H1 2025.","Plan to initiate Phase 2a POC trial in CF patients H2 2025 with topline data mid-2026; combination MAD trials also planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181754,"accession_number":"0001193125-25-023570","cik":2036042,"company_name":"Sionna Therapeutics, Inc.","ticker":"SION","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sionna adopts amended charter/bylaws with IPO completion; eliminates written consent","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended charter authorizes 500M common shares and 10M undesignated preferred shares; prior preferred series removed.","Stockholder ability to act by written consent or call special meetings eliminated.","Bylaws updated with advance notice procedures for stockholder proposals and director nominations.","Changes were previously disclosed in the S-1 and became effective upon January 31, 2025 IPO closing.","Governance structure now conforms to typical public company standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1950945755.4197562,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}